U.S. infectious diseases group seeks more data on Lilly COVID-19 antibody drug

By Deena Beasley (Reuters) - The Infectious Diseases Society of America (IDSA) on Thursday said it is evaluating the data on which U.S. regulators approved emergency use of Eli Lilly and Co's COVID-19 antibody drug, and noted that more information is needed. The medical association, which represents more than 12,000 specialists, said its guidelines panel is evaluating available trial data and will issue its recommendations soon.

Reuters November 13, 2020 00:05:43 IST
U.S. infectious diseases group seeks more data on Lilly COVID-19 antibody drug

US infectious diseases group seeks more data on Lilly COVID19 antibody drug

By Deena Beasley

(Reuters) - The Infectious Diseases Society of America (IDSA) on Thursday said it is evaluating the data on which U.S. regulators approved emergency use of Eli Lilly and Co's COVID-19 antibody drug, and noted that more information is needed.

The medical association, which represents more than 12,000 specialists, said its guidelines panel is evaluating available trial data and will issue its recommendations soon.

The Food and Drug Administration on Monday authorized Lilly’s bamlanivimab for people over age 65 recently diagnosed with mild-to-moderate COVID-19, and for patients age 12 and older who have an underlying risk factor for serious illness, such as obesity or diabetes. The agency said the drug should not be used in hospitalized patients.

"It is important for clinicians and members of the public to be aware that the available data are limited, and that more information is needed to determine the effect of this therapy on clinically meaningful outcomes," the IDSA said in a statement.

The association has updated its COVID-19 treatment guidelines several times over the course of the pandemic, adding drugs like Gilead Sciences Inc's antiviral remdesivir and generic steroids as trial data have emerged.

It does not always follow the lead of the FDA, which in August authorized emergency use of plasma derived from COVID-19 survivors for treating patients hospitalized with the illness. The IDSA still advises that convalescent plasma only be used in the context of a clinical trial.

"For new therapeutics to be used widely and routinely outside of clinical trials, we urge that there be sufficient safety and efficacy data to be confident regarding their use," the group said.

The IDSA said it is also concerned about the limited supply of the Lilly antibody treatment.

The Department of Health and Human Services said it has purchased 300,000 doses of the drug and will begin distributing them free-of-charge this week to state health departments.

(Reporting by Deena Beasley; Editing by Bill Berkrot)

This story has not been edited by Firstpost staff and is generated by auto-feed.

Updated Date:

TAGS:

also read

France, Germany to agree to NATO role against Islamic State - sources
| Reuters
World

France, Germany to agree to NATO role against Islamic State - sources | Reuters

By Robin Emmott and John Irish | BRUSSELS/PARIS BRUSSELS/PARIS France and Germany will agree to a U.S. plan for NATO to take a bigger role in the fight against Islamic militants at a meeting with President Donald Trump on Thursday, but insist the move is purely symbolic, four senior European diplomats said.The decision to allow the North Atlantic Treaty Organization to join the coalition against Islamic State in Syria and Iraq follows weeks of pressure on the two allies, who are wary of NATO confronting Russia in Syria and of alienating Arab countries who see NATO as pushing a pro-Western agenda."NATO as an institution will join the coalition," said one senior diplomat involved in the discussions. "The question is whether this just a symbolic gesture to the United States

China's Xi says navy should become world class
| Reuters
World

China's Xi says navy should become world class | Reuters

BEIJING Chinese President Xi Jinping on Wednesday called for greater efforts to make the country's navy a world class one, strong in operations on, below and above the surface, as it steps up its ability to project power far from its shores.China's navy has taken an increasingly prominent role in recent months, with a rising star admiral taking command, its first aircraft carrier sailing around self-ruled Taiwan and a new aircraft carrier launched last month.With President Donald Trump promising a US shipbuilding spree and unnerving Beijing with his unpredictable approach on hot button issues including Taiwan and the South and East China Seas, China is pushing to narrow the gap with the U.S. Navy.Inspecting navy headquarters, Xi said the navy should "aim for the top ranks in the world", the Defence Ministry said in a statement about his visit."Building a strong and modern navy is an important mark of a top ranking global military," the ministry paraphrased Xi as saying.